Our data suggests that the combination of VEGF inhibitors, such as bevacizumab, and mTOR pathway inhibitors, such as temsirolimus, should continue to be considered and tested as potential treatments or adjuncts for treatment of glioblastoma and other tumors. Here, VEGFA is linked to glioblastoma.